Loading stock data…
FBIO
$2.33+0.03 (+1.30%)
Market ClosedLast close May 1
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fortress Biotech, Inc. in the Healthcare sector is trading at $2.33. The stock is currently 49% below its 52-week high of $4.53, remaining 19.9% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why FBIO maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.33
Potential Upside
5%
Whystock Fair Value$2.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$72.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-182.85%
Volume
Today's trading volume
242,773
Recent News
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on Ja
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) business as it appears the...
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech: Q3 Earnings Snapshot
BAY HARBOR ISLAND, Fla. AP) — Fortress Biotech Inc. FBIO) on Friday reported earnings of $5.9 million in its third quarter.
Kamada (KMDA) Misses Q3 Earnings Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?